[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.232.62.209. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 3,675
Citations 0
This Week in JAMA
February 6, 2013

This Week in JAMA

JAMA. 2013;309(5):415. doi:10.1001/jama.2012.145196

Approximately one-third of patients with peripheral artery disease (PAD) experience intermittent claudication and associated lifestyle limitations. In a randomized placebo-controlled trial involving 212 Australian patients with PAD, Ahimastos and colleagues found that compared with placebo, 24-week treatment with ramipril—an angiotensin-converting enzyme inhibitor—was associated with increased pain-free and maximum walking times during a standard treadmill exercise test and improvement in patient-perceived physical functioning. In an editorial, McDermott discusses medical therapy for PAD.

SEE ArticleArticle AND AUTHOR AUDIO INTERVIEW

To assess the efficacies of common treatments for chronic lateral epicondylalgia, Coombes and colleagues randomly assigned 165 patients to receive 1 of the following 4 treatments: corticosteroid injection, placebo injection, corticosteroid injection plus physiotherapy (PT), or placebo injection plus PT. The 2 primary trial outcomes were patient-reported complete recovery or much improvement assessed at 1 year and 1-year disease recurrence rates. The authors report that compared with placebo injection, corticosteroid injection resulted in lower rates of complete recovery/much improvement at 1 year, as well as greater recurrence. The PT and no-PT groups did not differ in 1-year ratings of complete recovery/much improvement or recurrence.

×